Hepatocellular Carcinoma 2 Frederick R. Bentley, M.D. and Michael V. Beheshti, M.D. Recognize the additional challenges presented by cirrhosis and portal hypertension in patients with hepatocellular carcinoma (HCC). Utilize assessment tools for appropriate selection of patients for resection and liver transplantation. Explain the rationale for allocation of livers for transplantation. Evaluate patients for locoregional treatment of HCC. Compare and contrast the evidence supporting available locoregional therapies. CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Concerns in Hepatology Steven K. Herrine, M.D. and Charissa Y. Chang, M.D. Determine the underlying cause of unconjugated or conjugated hyperbilirubinemia. Differentiate biliary obstruction from infiltrative disease in a patient with elevated alkaline phosphatase levels. Work up patients who present with abnormal liver function tests. Identify and correct the precipitating factors in patients with hepatic encephalopathy (HE). Consider rifaximin as an alternative to lactulose in the management of patients with HE. CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Liver Diseases Marcelo Kugelmas, M.D. and Nancy S. Reau, M.D. Differentiate between nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis. Prevent the systemic effects of NAFLD. Advise and recommend lifestyle modifications to patients with NAFLD. Diagnose and manage primary sclerosing cholangitis and reduce risk for malignancies. Recognize the effects of certain gastrointestinal drugs on the liver. CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Update on HCV Robert R. Schade, M.D. and Adrian Di Bisceglie, M.D. Differentiate among the various tests for HCV and utilize the most appropriate test. Discuss the factors that affect response to therapy and progression of disease. Elaborate on the mechanism of action, characteristics, and advantages of telaprevir (TVR) and boceprevir (BOC). Manage the side effects and drug-drug interactions of TVR and BOC. Elaborate on newer drugs with different mechanisms of action and interferon-free therapy. CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Highlights from Topics in Women's Gastrointestinal Health Andelka LoSavio, M.D., Anjana Pillai, M.D. and Laura C. Michaelis, M.D. Recognize and interpret changes in GI laboratory findings and physiologic alterations unique to pregnancy. Recommend appropriate treatment plans for common GI disorders during pregnancy. Diagnose and manage liver diseases in women, with modification of treatments and delivery plans as needed during pregnancy. Differentiate among causes of anemia in women and assess for disorders associated with anemias. Confirm treatment success or manage treatment failure in patients with anemia. CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Additional Continuing Education Options Available...
If you have taken the current Hepatology seminar listed above or if you are seeking additional CE credits, please visit: Medical Courses Coming Soon .There you will find abbreviated listings of additional courses available and courses that will be available soon.
ASI Now Offers 9 NEW Specialties! Click the links below for the current course outline and full information!
Here is what our clients are saying about ASI's CME programs...
" The quality level of these flexible continuing medical education seminars is exceptional..the travel-friendly element to your program is ideal..I will continue to come to ASI for my CE needs! Thank you!" Taghi,P.A.,Boston, 7/2012
"...Excellent way to merge CME with a restful environment! I will recommend to my colleagues!" Ed, MD, NC, 9/2012
" This was my first time taking a course in Kissimmee, Florida. I loved the location and flexibility..this worked very well for me." Sara, CRNA, IN, 9/2012
Back to Top of the Hepatology CME Review Page